Parallax Volatility Advisers, L.P. Altimmune, Inc. Transaction History

Parallax Volatility Advisers, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	BUY	$8.43 - $16.81 $481,605 - $960,355	57,130 New	57,130 $646,000
Q2 2021 Aug 16, 2021	SELL	$9.85 - $16.46 $282,360 - $471,842	-28,666 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$12.71 - $24.31 $26,030 - $49,786	-2,048 Reduced 6.67%	28,666 $405,000
Q4 2020 Feb 16, 2021	BUY	$7.84 - $14.22 $240,797 - $436,753	30,714 New	30,714 $346,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $353M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.